A Phase 2 trial of AM 003 to evaluate AM003 safety and efficacy in combination with a checkpoint inhibitor in patients with advanced/metastatic solid tumors
Latest Information Update: 14 Nov 2024
Price :
$35 *
At a glance
- Drugs AM 0003 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2024 New trial record